EWTX News & Events

Cash, cash equivalents and marketable securities were approximately $530.1M as of December 31, 2025. "Following strong execution in 2025, we have entered a transformative year," said CEO Kevin Koch. "We remain on track to deliver pivotal GRAND CANYON top-line data for sevasemten, with the potential to support the first marketing application for the treatment of Becker. We also expect CIRRUS-HCM 12-week Part D results for EDG-7500 in HCM in the first half of 2026. Data from Part D will support refinement of our Phase 3 trial strategy in HCM. With multiple near-term catalysts and a high-performing team, we are closer than ever to delivering transformative medicines for patients living with serious conditions that still lack adequate treatment options and represent significant unmet medical needs."

Edgewise Therapeutics provided updates on its clinical programs and highlighted major milestones for 2026. 2026 priorities include: Sevasemten: complete the GRAND CANYON global pivotal cohort and announce top-line results in individuals with Becker in Q4, prepare for submission of an NDA with the FDA for sevasemten in Becker in 1H27; finalize the design and plan for a Phase 3 trial in individuals with Duchenne in 2H26. For EDG-7500: report data in individuals with obstructive and nonobstructive HCM in 1H26; initiate Phase 3 trial in obstructive and nonobstructive HCM in 2H26. For EDG-15400: report Phase 1 data of EDG-15400 in healthy adults in 1H26; initiate Phase 2 trial in participants with heart failure with preserved ejection fraction with results anticipated in 1H27.

Edgewise Therapeutics announced that on December 31, 2025, Edgewise granted inducement stock options to purchase a total of 119,250 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan.